Clinical Studies and Therapies in Parkinson's Disease
portes grátis
Clinical Studies and Therapies in Parkinson's Disease
Translations from Preclinical Models
Segura-Aguilar, Juan
Elsevier Science Publishing Co Inc
06/2021
306
Mole
Inglês
9780128221204
15 a 20 dias
450
Descrição não disponível.
1. Parkinson's disease
2. Parkinson?s pharmacological therapy
3. Dopamine synthesis
4. Dopamine storage and release
5. Dopamine oxidative deamination
6. Dopamine methylation
7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
9. Preclinical model based on exogenous neurotoxins for Parkinson's disease
10. Preclinical models based on genetic mutations associated with the familial form of Parkinson?s disease
11. Preclinical models based on endogenous neurotoxins
12. Conclusions
2. Parkinson?s pharmacological therapy
3. Dopamine synthesis
4. Dopamine storage and release
5. Dopamine oxidative deamination
6. Dopamine methylation
7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
9. Preclinical model based on exogenous neurotoxins for Parkinson's disease
10. Preclinical models based on genetic mutations associated with the familial form of Parkinson?s disease
11. Preclinical models based on endogenous neurotoxins
12. Conclusions
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alpha-synuclein; Alpha-synuclein aggregation; Animal science; Antidepressive; Anxiety; Autophagy dysfunction; Autosomal-dominant mutations; Autosomal-recessive mutations; Basal ganglia; Biochemical mechanism; Biochemistry; Biochemistry applications; Biochemistry methods; Biological process; Biological substances; Biomolecules; Body system; Calcium channel antagonists; Care; Cell biology; Cellular neuroscience; Chemical substance; Clinical neuroscience; Clinical studies; Cognitive decline; Cognitive neuroscience; Cognitive psychology; Constipation; Cooper; Corticotropin-releasing hormone; Dementia with Lewy bodies; Depression; Dopamine; Dopamine transporter; Drug-induced parkinsonism; Drugs; Endocrine system physiology; Endocrinology; Endogenous neurotoxin; Enzymology; Epidemiology; Excessive daytime somnolence; Genetic disorders; Genetic Parkinson's disease; Genetics; Idiopathic Parkinson's disease; Immunology; Insomnia; l-dopa; Leucine-rich repeat kinase-2; Lewy bodies; Maneb; Manganese; Medical biochemistry; Mental disorder; Mild cognitive impairment
1. Parkinson's disease
2. Parkinson?s pharmacological therapy
3. Dopamine synthesis
4. Dopamine storage and release
5. Dopamine oxidative deamination
6. Dopamine methylation
7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
9. Preclinical model based on exogenous neurotoxins for Parkinson's disease
10. Preclinical models based on genetic mutations associated with the familial form of Parkinson?s disease
11. Preclinical models based on endogenous neurotoxins
12. Conclusions
2. Parkinson?s pharmacological therapy
3. Dopamine synthesis
4. Dopamine storage and release
5. Dopamine oxidative deamination
6. Dopamine methylation
7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
9. Preclinical model based on exogenous neurotoxins for Parkinson's disease
10. Preclinical models based on genetic mutations associated with the familial form of Parkinson?s disease
11. Preclinical models based on endogenous neurotoxins
12. Conclusions
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alpha-synuclein; Alpha-synuclein aggregation; Animal science; Antidepressive; Anxiety; Autophagy dysfunction; Autosomal-dominant mutations; Autosomal-recessive mutations; Basal ganglia; Biochemical mechanism; Biochemistry; Biochemistry applications; Biochemistry methods; Biological process; Biological substances; Biomolecules; Body system; Calcium channel antagonists; Care; Cell biology; Cellular neuroscience; Chemical substance; Clinical neuroscience; Clinical studies; Cognitive decline; Cognitive neuroscience; Cognitive psychology; Constipation; Cooper; Corticotropin-releasing hormone; Dementia with Lewy bodies; Depression; Dopamine; Dopamine transporter; Drug-induced parkinsonism; Drugs; Endocrine system physiology; Endocrinology; Endogenous neurotoxin; Enzymology; Epidemiology; Excessive daytime somnolence; Genetic disorders; Genetic Parkinson's disease; Genetics; Idiopathic Parkinson's disease; Immunology; Insomnia; l-dopa; Leucine-rich repeat kinase-2; Lewy bodies; Maneb; Manganese; Medical biochemistry; Mental disorder; Mild cognitive impairment
